Corporate report

Section 5A drug driving lessons learnt review

Report looking at a quality failure in s5A drugs driving analysis.

• From: Forensic Science Regulator
• Published: 15 May 2024

Documents

Lessons learnt review: quality failure in s5A drugs driving analysis (accessible)

Ref: FSR-REP-0001

HTML

Lessons learnt review: quality failure in s5A drugs driving analysis

Ref: FSR-REP-0001

PDF, 313 KB, 28 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This report is aimed at practitioners and forensic units undertaking drug driving toxicology testing and other stakeholders with an interest in this area.

This report looks at a significant quality failure in the provision of drugs driving analysis which resulted in more than 1,700 reported results being rescinded.

This report considers the events, decisions and organisational responses that led to this quality failure through 4 key areas:

• root cause
• wider organisational risk management processes
• accreditation and regulatory processes
• effectiveness of regulatory requirements.

This report outlines lessons learnt from these key areas and identifies where actions should be taken to reduce the risk of a similar failure in the future.

The regulator will follow up on the learning points identified in this report through:

• making amendments to the code of practice
• engagement with stakeholders
• reporting on progress and outcomes through the FSR annual report

Published 15 May 2024